Abstract:In the online version of the article titled 'Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma' published in Current Molecular Pharmacology (2024; 2: e18761429290933), a change was made in the author position. [1]. The original article can be found online at: https://www.eurekaselect.com/article/139869 Original: Yunzhi Zhu 1,3,# , Yi Hu 2,# , Chengsheng Yang 1 , Shipu Huang 1 , Jianping Wen 4,# , Weiguo Huang 1,3,# and Shengjun Xiao 1,3,* Corrected: Yunzhi Zhu 1,3,# , Yi Hu 2,# , Chengsheng Yang 1 , Shipu Huang 1 , Jianping Wen 4,* , Weiguo Huang 1,3,* and Shengjun Xiao 1,3,*

Correction: Simionescu et al. The Multifaceted Role of Extracellular Vesicles in Glioblastoma: microRNA Nanocarriers for Disease Progression and Gene Therapy. Pharmaceutics 2021, 13, 988

Circ0021205 Aggravates the Progression of Non-Small Cell Lung Cancer by Targeting Mirna-16-5p/vegfa

Correction: Yadav et al. PLGA-Quercetin Nano-Formulation Inhibits Cancer Progression via Mitochondrial Dependent Caspase-3,7 and Independent FoxO1 Activation with Concomitant PI3K/AKT Suppression. Pharmaceutics 2022, 14, 1326

Correction: Ci et al. Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer. Pharmaceutics 2019, 11, 15

Correction: Zhang et al. Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli. Pharmaceutics 2022, 14, 1804

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Correction: Russo et al. The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis. Cancers 2022, 14, 198

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471]

Correction: MiR-4458-loaded gelatin nanospheres target COL11A1 for DDR2/SRC signaling pathway inactivation to suppress the progression of estrogen receptor-positive breast cancer

Erratum: Author correction to 'VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity' [Acta Pharm Sin B 11 (2021) 420-433]

Correction: Highly Penetrative Liposome Nanomedicine Generated by a Biomimetic Strategy for Enhanced Cancer Chemotherapy.

Correction: Musumeci et al. Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. Biomedicines 2022, 10, 985

Erratum: Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI: Erratum

Erratum: First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Author Correction to ‘pharmacologically Targeting Molecular Motor Promotes Mitochondrial Fission for Anti-Cancer’ [acta Pharm Sin B 11 (2021) 1853–1866]

Correction: Cheng et al. Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways. Cells 2022, 11, 3232

Corrigendum to “Transferrin-Guided Intelligent Nanovesicles Augment the Targetability and Potency of Clinical PLK1 Inhibitor to Acute Myeloid Leukemia” [bioact. Mater. 21 (march 2023) 499–510]